Smith Asset Management Group LP reduced its stake in shares of FibroGen, Inc (NASDAQ:FGEN) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,470 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Smith Asset Management Group LP’s holdings in FibroGen were worth $338,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Bank of New York Mellon Corp increased its stake in FibroGen by 3.7% in the first quarter. Bank of New York Mellon Corp now owns 244,141 shares of the biopharmaceutical company’s stock valued at $6,018,000 after buying an additional 8,634 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in FibroGen during the first quarter valued at about $1,133,000. American Century Companies Inc. increased its stake in FibroGen by 35.0% in the first quarter. American Century Companies Inc. now owns 250,051 shares of the biopharmaceutical company’s stock valued at $6,164,000 after buying an additional 64,760 shares during the last quarter. Algert Global LLC increased its stake in FibroGen by 6.4% in the first quarter. Algert Global LLC now owns 24,322 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 1,466 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in FibroGen by 29.0% in the first quarter. Wells Fargo & Company MN now owns 62,037 shares of the biopharmaceutical company’s stock valued at $1,529,000 after buying an additional 13,928 shares during the last quarter. 43.03% of the stock is owned by institutional investors and hedge funds.

Shares of FibroGen, Inc (NASDAQ FGEN) opened at 44.05 on Tuesday. The company has a 50-day moving average of $35.25 and a 200 day moving average of $28.50. The firm’s market cap is $3.14 billion. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $51.70.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The firm had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. On average, equities analysts expect that FibroGen, Inc will post ($1.82) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Smith Asset Management Group LP Decreases Position in FibroGen, Inc (NASDAQ:FGEN)” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/smith-asset-management-group-lp-decreases-position-in-fibrogen-inc-nasdaqfgen/1489588.html.

Several analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price target for the company. in a research report on Friday, July 21st. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Leerink Swann reissued an “outperform” rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. Finally, Citigroup Inc. lifted their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $60.17.

In other FibroGen news, insider K Peony Yu sold 37,500 shares of the stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.58, for a total value of $1,896,750.00. Following the completion of the transaction, the insider now owns 236,507 shares in the company, valued at $11,962,524.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Pat Cotroneo sold 2,891 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $28.75, for a total value of $83,116.25. Following the completion of the transaction, the vice president now owns 163,366 shares of the company’s stock, valued at approximately $4,696,772.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 477,938 shares of company stock valued at $17,570,645. 14.90% of the stock is owned by corporate insiders.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.